Treatment
Rituximab clinical trials
We’re tracking 267 recruiting studies that include Rituximab, each written for real people, not researchers, below.
Recruiting studies
- NCT07208981RecruitingPhase 2
Orelabrutinib, zebetuzumab, and lenalidomide for new MZL
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
Nanjing, JiangsuAges 18–75 - NCT04494503RecruitingPhase 1/Phase 2
Study drug for hard-to-treat CLL or SLL after relapse
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT07168980RecruitingPhase 2/Phase 3
Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT07168161RecruitingPhase 3
BDB-001 for ANCA vasculitis (GPA/MPA) trial
This trial tests a new drug called BDB-001 for people with a type of blood vessel inflammation (ANCA vasculitis, specifically GPA or MPA). It aims to see if adding BDB-001 to standard treatment can help control the disease better.
Beijing, Beijing MunicipalityAges 18–75 - NCT07139873RecruitingPhase 3
Study of DZD8586 vs. standard care for relapsed CLL or SLL
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
Nanjing, JiangsuAges 18 years+ - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Phoenix, ArizonaAges 18 years+ - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07072208Recruiting
A Study of Four Drugs for Older Adults with DLBCL
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Suzhou, JiangsuAges 70 years+ - NCT06980584Recruiting
Treating nonthrombotic pulmonary hypertension from fibrosing mediastinitis
This study tests a treatment for a rare lung condition called fibrosing mediastinitis, where scar tissue in the chest presses on the lung artery, causing high blood pressure in the lungs. The goal is to see if the treatment can improve your symptoms and quality of life.
BeijingAges 18–85 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07037732Recruiting
Monitoring rituximab in autoimmune diseases
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Nice, Alpes MaritimesAges 18 years+ - NCT07029737RecruitingPhase 2
Studying acalabrutinib with R-CHOP for untreated mantle cell lymphoma
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
A CoruñaAges 18–130 - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Aurora, ColoradoAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT06983821RecruitingPhase 3
Low-dose steroids for kidney disease from vasculitis
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
Hamilton, OntarioAges 18 years+ - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06973811RecruitingPhase 2
ZR-MTX for Newly Diagnosed Eye Lymphoma
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06933134Recruiting
Using a biomarker to guide low-dose rituximab in rheumatoid arthritis
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
ToursAges 18 years+
Common questions
- Are there clinical trials studying Rituximab?
- Yes. Clin2 currently lists 267 recruiting studies that include Rituximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Rituximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Rituximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Rituximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.